| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Targets are cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2); oxaprozin is a non-selective NSAID that inhibits both isoforms, blocking arachidonic acid conversion to pro-inflammatory prostaglandins; cell-based assays indicate lower COX-2 selectivity, implying relatively higher COX-1 inhibition compared with COX-2-selective agents.
|
|---|---|
| ln Vitro |
Apoptosis is induced by oxaprozin (0-100 μM) in a dose-dependent manner. When caspase-3 is engaged, oxaprozin boosts its activity; however, when it is at rest, it does not. At 50 μM, oxaprozin suppresses the activation of NF-κB. The agent IκBα-induced activation of the IKK system is inhibited by oxaprozin [1]. In monocytes treated with CD40L, oxaprozin at a concentration of 100 μM had the greatest proapoptotic effect, leading to a considerable increase in apoptosis. Treatment with oxiprozin prevents Akt and NF-κB (p65) phosphorylation produced by CD40L [2].
Oxaprozin potassium is a potent inhibitor of prostaglandin synthesis in vitro, reversibly and competitively inhibiting COX-1 and COX-2; it is a non-selective NSAID with higher COX-1 selectivity in cell-based assay systems, and its anti-inflammatory activity is attributed to blockade of prostaglandin production in platelets and inflammatory cells. |
| ln Vivo |
In vivo, oxaprozin potassium dissociates into the active moiety oxaprozin and produces anti-inflammatory, analgesic, and antipyretic effects in animal models and humans; it is used for rheumatoid arthritis, osteoarthritis, dysmenorrhea, and moderate pain, with efficacy linked to sustained COX-1/COX-2 inhibition and prostaglandin suppression.
|
| Enzyme Assay |
COX-1 and COX-2 enzymatic activity is measured by incubating recombinant or purified COX enzymes with arachidonic acid in the presence of graded oxaprozin potassium concentrations; prostaglandin E2 formation is quantified by ELISA or LC-MS/MS, and IC50 values are calculated for each isoform; selectivity is determined by comparing COX-1 and COX-2 inhibition under identical conditions.
|
| Cell Assay |
Inflammatory cells (e.g., macrophages, platelets) or COX-expressing cell lines are treated with oxaprozin potassium in the presence or absence of arachidonic acid or inflammatory stimuli; PGE2 production is measured by ELISA, COX-1/COX-2 protein expression by Western blotting, and cell viability by metabolic assays; whole-blood assays assess platelet COX-1 inhibition.
|
| Animal Protocol |
Rats or mice with carrageenan-induced paw edema, adjuvant arthritis, or other inflammatory models receive oxaprozin potassium by oral gavage at doses selected from pharmacokinetic studies; paw volume, inflammatory cytokine levels, and prostaglandin E2 in exudates are measured, and gastric mucosal tolerability is assessed by histology to evaluate COX-1-related gastrointestinal effects.
|
| References |
|
| Additional Infomation |
Oxaprozin potassium is the potassium salt form of Oxaprozin, belonging to the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAIDs). It has anti-inflammatory, analgesic, and antipyretic effects. Oxaprozin potassium reversibly and competitively inhibits cyclooxygenase (COX), thereby blocking the conversion of arachidonic acid into pro-inflammatory prostaglandins. This inhibits the production of prostaglandins involved in pain, inflammation, and fever.
See also: Oxaprozin (with active fraction). |
| Molecular Formula |
C18H14NO3-.K+
|
|---|---|
| Molecular Weight |
331.41
|
| Exact Mass |
331.061
|
| CAS # |
174064-08-5
|
| Related CAS # |
Oxaprozin;21256-18-8;Oxaprozin-d4
|
| PubChem CID |
23694685
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
467ºC at 760mmHg
|
| Flash Point |
236.2ºC
|
| Vapour Pressure |
1.6E-09mmHg at 25°C
|
| LogP |
2.691
|
| tPSA |
66.16
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[K+].O=C(CCC1=NC(C2C=CC=CC=2)=C(C2C=CC=CC=2)O1)[O-]
|
| InChi Key |
QTAQWNSMRSLSCG-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C18H15NO3.K/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14;/h1-10H,11-12H2,(H,20,21);/q;+1/p-1
|
| Chemical Name |
potassium;3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0174 mL | 15.0871 mL | 30.1741 mL | |
| 5 mM | 0.6035 mL | 3.0174 mL | 6.0348 mL | |
| 10 mM | 0.3017 mL | 1.5087 mL | 3.0174 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.